ARISE II Consensus on the Management of Intracranial Atherosclerotic Disease.

Stroke 2025 Vol.56(6) p. 1636-1641

Tjoumakaris SI, Roy JM, Amin-Hanjani S, Charbel FT, Dabus G, Fisher M, Gounis M, Hoh BL, Liebeskind DS, Linfante I, Samaniego EA, Toth G, Zaidat OO, Bhogal P, Arthur A, Wakhloo AK

Abstract

Intracranial atherosclerotic disease (ICAD) is one of the leading causes of ischemic stroke worldwide. Despite advances in its diagnosis and management, there is no clear consensus on best practices to manage ICAD. This report summarizes the ARISE II (Roundtable Discussion With Industry and Stroke Experts) consensus in treating ICAD. The consensus underscored the importance of lifestyle modification and medical management in patients with ICAD. Patients who fail medical management are candidates for endovascular treatment. Open surgery is not recommended in patients who lack demonstrated hemodynamic insufficiency. The consensus also identified gaps in knowledge about the optimal duration of antithrombotics, the effect of the CYP2C19 genotype on medical management, the need for newer devices, and the standardization of antithrombotic protocols before stenting in an acute setting. Optical coherence tomography requires additional clinical data before defining its role in the diagnosis of ICAD.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 endovascular scispacy 1
합병증 Intracranial Atherosclerotic scispacy 1
질환 Intracranial Atherosclerotic scispacy 1
질환 Intracranial atherosclerotic disease C0007775
Cerebral Atherosclerosis
scispacy 1
질환 ischemic stroke C0948008
Ischemic stroke
scispacy 1
질환 Stroke C0038454
Cerebrovascular accident
scispacy 1
질환 hemodynamic insufficiency scispacy 1
기타 ICAD → Intracranial atherosclerotic disease scispacy 1
기타 patients scispacy 1
기타 CYP2C19 scispacy 1

MeSH Terms

Humans; Intracranial Arteriosclerosis; Endovascular Procedures; Stents; Disease Management; Fibrinolytic Agents; Ischemic Stroke